Arthritis News and Research

Latest Arthritis News and Research

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Study reports new mechanism that regulates specification of lymphocytes

Study reports new mechanism that regulates specification of lymphocytes

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Nurse practitioners can play crucial role in treating chronic geriatric conditions, shows study

Nurse practitioners can play crucial role in treating chronic geriatric conditions, shows study

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

Manchester researchers launch new project to better understand causes of RA

Manchester researchers launch new project to better understand causes of RA

MorphoSys, Celgene agree to jointly develop MOR202 for patients with multiple myeloma

MorphoSys, Celgene agree to jointly develop MOR202 for patients with multiple myeloma

Karo Bio extends research collaboration with Pfizer on RORgamma modulators

Karo Bio extends research collaboration with Pfizer on RORgamma modulators

Researchers provide new revelations about intricate pathways involved in turning on T cells

Researchers provide new revelations about intricate pathways involved in turning on T cells

TSRI scientists find dual inhibitor that attacks two enzymes associated with Parkinson's disease

TSRI scientists find dual inhibitor that attacks two enzymes associated with Parkinson's disease

MMR booster does not result in worse JIA disease activity in children

MMR booster does not result in worse JIA disease activity in children

Scientists discover new anti-tuberculosis compound that kills drug-resistant TB bacteria

Scientists discover new anti-tuberculosis compound that kills drug-resistant TB bacteria

TWi Biotechnology completes patient enrollment in phase II trial of AC-201 for Gout Flare Prophylaxis

TWi Biotechnology completes patient enrollment in phase II trial of AC-201 for Gout Flare Prophylaxis

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Mayo researchers find rheumatic condition gout may be due to flare-ups in other joints

Mayo researchers find rheumatic condition gout may be due to flare-ups in other joints

Study shows patients with avascular necrosis have turned to stem cell therapy for aid

Study shows patients with avascular necrosis have turned to stem cell therapy for aid

MemoryShape Breast Implants receive FDA approval

MemoryShape Breast Implants receive FDA approval

Researchers at Albert Einstein College of Medicine convene one-day conference on Jewish genetics

Researchers at Albert Einstein College of Medicine convene one-day conference on Jewish genetics

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Study demonstrates efficacy of canakinumab at tapering corticosteroid use in patients with SJIA

Study demonstrates efficacy of canakinumab at tapering corticosteroid use in patients with SJIA

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.